Makes research reagents, proteins, antibodies and diagnostic tools used by biotech, pharma and academic labs for life-sciences research.
Makes research reagents, proteins, antibodies and diagnostic tools used by biotech, pharma and academic labs for life-sciences research.
Most sales are small repeat orders for catalog proteins and antibodies, which labs reorder as they run experiments; instruments such as automated protein analyzers then pull through reagent sales. Diagnostics and spatial-biology tests, built up through acquisitions such as Advanced Cell Diagnostics in 2017, are the other main line.
Moat: narrow (brand, scale, distribution). A broad catalog and established brand recognition (R&D Systems) among life-sciences researchers support recurring sales.
Headquarters: Minneapolis, Minnesota, US · Founded: 1976 · Employees: 3,000
Size Bio-Techne (TECH) is a United States Health Care company (Biotechnology) with a market value of $11.4B, the 714th largest of 3,085 United States companies the cockpit tracks. Shares closed at $72.75 on 18 Nov 2026.
Performance Over six months the shares gained 55.8%, against +23.0% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 0.9% over the last twelve months (peer median +32.0%); the operating margin is 21.3% (peer median 8.5%).
Valuation It trades at 34.4× forward earnings against a peer median of 28.5× (6th cheapest of 11).
Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.5 points below its cost of capital (11.4% WACC).
Short interest Short interest is 4.9% of the free float (30 Oct 2026).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $1.23B | $1.22B | $1.22B | $1.16B | $1.14B |
| Revenue growth | — | 0% | +5% | +2% | — |
| Gross profit | $810M | $779M | $779M | $773M | $770M |
| EBITDA | $359M | $373M | $363M | $387M | $388M |
| Net income | $172M | $182M | $73.4M | $168M | $285M |
| Free cash flow | $308M | $263M | $257M | $236M | $216M |
| Capital expenditure | $29.4M | $28.9M | $31.0M | $62.9M | $38.2M |
| Total debt | $286M | $289M | $444M | $420M | $455M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bio-Techne TECH | $11.4B | +56% | +1% | 21% | 34.4× | 31.6% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Danaher DHR | $161B | +34% | +6% | 21% | 25.1× | 20.8% |
| Sartorius SRT.DE | $19.9B | +26% | +4% | 18% | 43.0× | 25.6% |
| Bio-Rad Laboratories BIO | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TECH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | -5.4% | 9th highest of 21 |
| 6-month return | +55.8% | +23.0% | 5th highest of 21 |
| Distance from 52-week high | -0.2% | -26.2% | highest of 21 |
| Revenue growth (TTM) | +0.9% | +32.0% | 4th lowest of 17 |
| Operating margin | 21.3% | 8.5% | 6th highest of 17 |
| Forward P/E | 34.4× | 28.5× | 6th cheapest of 11 |
| Growth the price implies (Req g, 7 yrs) | 31.6% | 10.7% | 4th most demanding of 11 |
| Growth delivered (Del g) | +5.5% | +18.2% | 3rd lowest of 11 |
| Hurdle (Req g minus delivered) | +26.2 pp | -7.3 pp | 2nd most demanding of 11 |
| ROIC minus cost of capital | -1.5 pp | -5.7 pp | 8th highest of 16 |
| EV / EBITDA | 31.7× | 16.0× | 4th most expensive of 9 |
| Net debt / EBITDA | -0.2× | -1.1× | 4th most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bio-Techne TECH | United States | $11.4B | +56% | +1% | 21% | 34.4× | 31.6% | +5.5% |
| BioMarin Pharmaceutical BMRN | United States | $11.9B | +22% | +20% | 19% | 11.2× | 8.2% | +12.0% |
| Cspc Pharma 1093.HK | Hong Kong | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% | +0.1% |
| Halozyme Therapeutics HALO | United States | $10.9B | +39% | +45% | 57% | 9.5× | -0.3% | +39.2% |
| Kymera Therapeutics KYMR | United States | $10.3B | +50% | +134% | -396% | n/a | n/a | n/a |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 35.6× | 6.2% | +2.3% |
| Elanco Animal Health ELAN | United States | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% | +7.6% |
| Krystal Biotech KRYS | United States | $9.34B | +4% | +26% | 48% | 36.3× | 13.1% | +26.0% |
| Vaxcyte PCVX | United States | $9.26B | +24% | n/a | n/a | n/a | n/a | n/a |
| ALTEOGEN 196170.KS | South Korea | $8.80B | -56% | +61% | 53% | 42.0× | 24.6% | +38.5% |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | 12% | 294.1× | 36.9% | +19.8% |
| BridgeBio Pharma BBIO | United States | $15.2B | +14% | +167% | -37% | n/a | n/a | n/a |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | n/a | n/a | n/a |
| Neurocrine Biosciences NBIX | United States | $16.5B | +5% | +38% | 25% | 18.0× | -1.5% | +22.3% |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | n/a | 47.2% | +16.6% |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | n/a | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 77.1× | n/a | n/a |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| BioNTech SE Sponsored ADR BNTX | United States | $20.6B | -8% | -21% | -61% | n/a | n/a | n/a |